Page 104 - Clinical Program In Primary Sclerosing Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical program in primary sclerosing cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program In Primary Sclerosing Cholangitis Today - Breaking & Trending Today

DGAP-News: DEBx Medical B.V.: DEBx Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal, Wounds

(1)
DGAP-News: DEBx Medical B.V.
/ Key word(s): Scientific publication
DEBx Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal, Wounds
16.02.2021 / 09:30
DEB
x Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal,
Wounds
(R)) removes biofilm and pathogens, enabling the natural healing process to start
[1]
- Case series (n = 10) demonstrated full granulation of wound bed in all patients within 12 weeks after one-time application of desiccant agent
[1]
[1]
[2] with different healing outcomes based on the woundsize and etiology of the wound
[3]
Rotterdam, The Netherlands, February 16, 2021 - DEB ....

Zuid Holland , South Africa , Noord Brabant , Alberto Cogo , Carlo Alberto Bignozzi , Brigitte Keller , Kostenloser Wertpapierhandel , Anne Marieke Ezendam , Bertj Quint , Bert Quint , Mc Services , Strategic Communications , Value Health , News Service , Distribution Services , Healing Process , Chronic Wounds Using , Novel Desiccant , Prospective Case , Marieke Ezendam , Kyu Cho , Corporate News , Regulatory Announcements , Medi Cal , நூற்த் துணிச்சலான , ஆல்பர்டோ கோகோ ,

New CMO to advance Clinical Pipeline Development

Feb 16 2021 Read 304 Times
Dr Gerard Short, MBBS has joined biotech VarmX, a company focusing on innovative approaches for the reversal of anticoagulation, as Chief Medical Officer (CMO). He will be responsible for overseeing the clinical development of the company’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.
With more than 20 years working with both big pharma and biotechs, Dr Short’s clinical development expertise has a particular focus on rare diseases and gene therapy for haematological disorders. He joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science, establishing an in-house pharmacovigilance function and advancing gene therapy clinical programmes in haemophilia B and Fabry’s disease. During a decade at Genzyme, he led the Global Development Team treatment programmes targeting Pompe’s disease (phase 3) ....

United Kingdom , City Of , Alexander Vos , London Business School , Member Of The Royal College Physicians , Imperial College , Master Of Business Administration , Mary Hospital Medical School , Global Development Team , Chief Medical Officer , Freeline Therapeutics , Hospital Medical School , Business Administration , London Business , Royal College , Pharmaceutical Medicine , Medi Cal , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , அலெக்சாண்டர் வாஸ் , லண்டன் வணிக பள்ளி , உறுப்பினர் ஆஃப் தி அரச கல்லூரி மருத்துவர்கள் , ஏகாதிபத்தியம் கல்லூரி , மேரி மருத்துவமனை மருத்துவ பள்ளி , உலகளாவிய வளர்ச்சி அணி , தலைமை மருத்துவ அதிகாரி ,

LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD patients

(1)
SEATTLE, Feb. 16, 2021 /PRNewswire/ LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients.
A total of 23 eyes from 15 subjects with intermediate Dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda
Light Delivery System (3 times per week for 3 weeks). Subjects were tested for safety and functional vision improvements using the Diopsys electroretinogram (ERG) device. ERG is a diagnostic test that measures the electrical activity of the retina of the eye in response to a light stimulus. All subjects were tested at weekly intervals for ERG function prior to the start of the next week of PBM treatments. An interim analysis was performed following the Month 1 study visit. The study was conducted by Dan Montzka, M.D. and Larry Perich, D.O. at the Perich Eye Cen ....

United States , Larry Perich , Kostenloser Wertpapierhandel , Dan Montzka , Perich Eye Center New Port Richey , Diopsys Inc , European Union , Food Drug Administration , Prnewswire Lumithera Inc , Lumithera Inc , Thera Inc , Delivery System , Perich Eye Center , New Port Richey , Visual Evoked Potential , Testing System , Valeda Light Delivery System , Drug Administration , ஒன்றுபட்டது மாநிலங்களில் , ஐரோப்பிய தொழிற்சங்கம் , தேரா இன்க் , டெலிவரி அமைப்பு , புதியது போர்த் பணக்காரர் , சோதனை அமைப்பு ,

iBiopsy: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy Clinical Development Plan on Lung Cancer Screening (LCS)

(1)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions.
The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.
First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low Dose Computed Tomography (LDCT) scans, strengthening its positioning in early-stage diagnosis, such as early-stage liver cancer diagnosis and non-alcoholic steatohepatitis (NASH) identification. ....

Emmanuelle Leygues , Ghislaine Gasparetto , Caroline Carmagnol , Biopsy Clinical Development Plan , United States Preventive Services Task Force , European Fund For Strategic Investments , Head Of Corporate Communications , European Investment Bank , Low Dose Computed Tomography , Fredrik Brag , Artificial Intelligence , Data Science , Juncker Plan , European Fund , Strategic Investments , Median Technologies , Imaging Phenomics , Euronext Growth , Euronext European Rising Tech , Corporate Communications , பயாப்ஸி மருத்துவ வளர்ச்சி திட்டம் , ஒன்றுபட்டது மாநிலங்களில் ப்ரெவெஂடிவ் சேவைகள் பணி படை , ஐரோப்பிய நிதி க்கு மூலோபாய முதலீடுகள் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் , ஐரோப்பிய முதலீடு வங்கி , செயற்கை உளவுத்துறை ,

LBP Data shows Potential for Clinical Development

Biotherapeutics company 4D pharma (Leeds) has announced progress on its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518, an ongoing Phase I/II clinical trial in combination with immune checkpoint inhibitor (ICI) Keytruda(R) (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with advanced malignancies who have previously progressed on ICI therapy. Click to read more. ....

Alex Stevenson , Scientific Officer , Bio Therapeutics , அலெக்ஸ் ஸ்டீவன்சன் , அறிவியல் அதிகாரி , உயிர் சிகிச்சை ,